Genomic Vision (GV.PA) Stock Price & Overview
EPA:GV • FR0011799907
The current stock price of GV.PA is 0.0018 EUR. Today GV.PA is up by 5.88%. In the past month the price decreased by -37.93%. In the past year, price decreased by -97.79%.
GV.PA Key Statistics
- Market Cap
- 693.191K
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.11
- Dividend Yield
- N/A
GV.PA Stock Performance
GV.PA Stock Chart
GV.PA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to GV.PA. When comparing the yearly performance of all stocks, GV.PA is a bad performer in the overall market: 99.81% of all stocks are doing better.
GV.PA Earnings
GV.PA Forecast & Estimates
GV.PA Groups
Sector & Classification
GV.PA Financial Highlights
Over the last trailing twelve months GV.PA reported a non-GAAP Earnings per Share(EPS) of -0.11. The EPS decreased by -14.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -268.44% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GV.PA Ownership
GV.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 25.5 | 38.133B | ||
| ARGX | ARGENX SE | 25.4 | 38.12B | ||
| 22UA | BIONTECH SE-ADR | N/A | 18.515B | ||
| ABVX | ABIVAX SA | N/A | 8.129B | ||
| 2X1 | ABIVAX SA | N/A | 8.097B | ||
| GXE | GALAPAGOS NV | N/A | 1.831B | ||
| GLPG | GALAPAGOS NV | N/A | 1.827B | ||
| NANO | NANOBIOTIX | N/A | 1.328B | ||
| IVA | INVENTIVA SA | N/A | 1.098B | ||
| 6IV | INVENTIVA SA | N/A | 1.098B | ||
| PHIL | PHILOGEN SPA | 18.09 | 663.748M | ||
| XUP | GENFIT | N/A | 468.027M | ||
| GNFT | GENFIT | 831.37 | 435.275M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About GV.PA
Company Profile
Génomic Vision SA is a molecular diagnostics and technology company, which develops and commercializes research tools and tests for the early detection of cancers and genetic diseases. The company is headquartered in Bagneux, Ile-De-France and currently employs 37 full-time employees. The company went IPO on 2014-04-02. The company develops and commercializes single-DNA molecule diagnostic tests and research tools for life sciences, cancer and genetic diseases. The firm uses the molecular combining technique for the direct visualization of single DNA molecules to detect quantitative and qualitative changes in the genome landscape and establish their contribution to pathology. The company develops its products and services in three main markets: the medical diagnostic market focusing on DNA diagnostics (cancer genomics, genetic diseases); the pharmaceutical research and development market in the fields of genomics, to develop tests that can help physicians identify how patients are likely to respond to targeted therapies (personalized medicine, pharmacogenomics, cancer cell proliferation); and the academic laboratories research market, providing molecular combining tools for academic research in the field of cancer genetics, cytogenetics and DNA replication.
Company Info
IPO: 2014-04-02
Genomic Vision
Green Square Batiment E, 80-84 rue des Meuniers
Bagneux ILE-DE-FRANCE FR
Employees: 37
Phone: 33149080740.0
Genomic Vision / GV.PA FAQ
What does Genomic Vision do?
Génomic Vision SA is a molecular diagnostics and technology company, which develops and commercializes research tools and tests for the early detection of cancers and genetic diseases. The company is headquartered in Bagneux, Ile-De-France and currently employs 37 full-time employees. The company went IPO on 2014-04-02. The company develops and commercializes single-DNA molecule diagnostic tests and research tools for life sciences, cancer and genetic diseases. The firm uses the molecular combining technique for the direct visualization of single DNA molecules to detect quantitative and qualitative changes in the genome landscape and establish their contribution to pathology. The company develops its products and services in three main markets: the medical diagnostic market focusing on DNA diagnostics (cancer genomics, genetic diseases); the pharmaceutical research and development market in the fields of genomics, to develop tests that can help physicians identify how patients are likely to respond to targeted therapies (personalized medicine, pharmacogenomics, cancer cell proliferation); and the academic laboratories research market, providing molecular combining tools for academic research in the field of cancer genetics, cytogenetics and DNA replication.
Can you provide the latest stock price for Genomic Vision?
The current stock price of GV.PA is 0.0018 EUR. The price increased by 5.88% in the last trading session.
Does Genomic Vision pay dividends?
GV.PA does not pay a dividend.
How is the ChartMill rating for Genomic Vision?
GV.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the ownership structure of Genomic Vision (GV.PA)?
You can find the ownership structure of Genomic Vision (GV.PA) on the Ownership tab.